Literature DB >> 224211

Translation of encephalomyocarditis virus RNA in reticulocyte lysates: kinetic analysis of the formation of virion proteins and a protein required for processing.

D S Shih, C T Shih, D Zimmern, R R Rueckert, P Kaesberg.   

Abstract

In cell-free extracts derived from rabbit reticulocytes, encephalomyocarditis RNA can be translated completely, and the products can be processed extensively to give encephalomyocarditis virion proteins and several nonvirion proteins, including a genome-coded protein required for processing. The latter is probably a protease. Translation is very efficient. Under typical conditions, each EMC RNA is translated approximately eight times during a 3-h period. Kinetic analyses (time-course experiments, pulse-chase experiments, and pulse-stop experiments) have been used to determine the time of appearance of major products, and these times have been correlated with map positions. The gene for the putative protease is located near the middle of the genome downstream from the virion protein genes. Ribosomes can travel the length of encephalomycarditis RNA within 30 min, but there is a delay in their progress along the RNA at some point soon after they traverse the region coding for virion protein precursors. This delay results in the accumulation of precursors for a period of about 10 min before the putative protease is made and virion proteins (epsilon, alpha, and gamma) are released by proteolysis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 224211      PMCID: PMC353350     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Identification of a viral protein involved in post-translational maturation of the encephalomyocarditis virus capsid precursor.

Authors:  C Lawrence; R E Thach
Journal:  J Virol       Date:  1975-04       Impact factor: 5.103

2.  Complete translation of encephalomyocarditis virus RNA and faithful cleavage of virus-specific proteins in a cell-free system from Krebs-2 cells.

Authors:  Y V Svitkin; V I Agol
Journal:  FEBS Lett       Date:  1978-03-01       Impact factor: 4.124

3.  Translation of encephalomyocarditis virus RNA in vitro yields an active proteolytic processing enzyme.

Authors:  H R Pelham
Journal:  Eur J Biochem       Date:  1978-04-17

4.  Cell-free synthesis and processing of the proteins of poliovirus.

Authors:  D S Shih; C T Shih; O Kew; M Pallansch; R Rueckert; P Kaesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

5.  Cleavage of mengovirus polyproteins in vivo.

Authors:  J Lucas-Lenard
Journal:  J Virol       Date:  1974-08       Impact factor: 5.103

6.  Characterization of the large picornaviral polypeptides produced in the presence of zinc ion.

Authors:  B E Butterworth; B D Korant
Journal:  J Virol       Date:  1974-08       Impact factor: 5.103

7.  Synthesis of viral-specific polypeptides in Mengo virus-infected L cells: evidence for asymmetric translation of the viral genome.

Authors:  E Paucha; J Seehafer; J S Colter
Journal:  Virology       Date:  1974-10       Impact factor: 3.616

8.  An efficient mRNA-dependent translation system from reticulocyte lysates.

Authors:  H R Pelham; R J Jackson
Journal:  Eur J Biochem       Date:  1976-08-01

9.  3'-terminal nucleotide sequence of encephalomyocarditis virus RNA determined by reverse transcriptase and chain-terminating inhibitors.

Authors:  D Zimmern; P Kaesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

10.  A comparative study on translation of flavivirus and picornavirus RNAs in vitro: apparently different modes of protein synthesis.

Authors:  Y V Svitkin; V N Lyapustin; V A Lashkevich; V I Agol
Journal:  FEBS Lett       Date:  1978-12-01       Impact factor: 4.124

View more
  53 in total

1.  Protease required for processing picornaviral coat protein resides in the viral replicase gene.

Authors:  A C Palmenberg; M A Pallansch; R R Rueckert
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

2.  Site-specific mutations at a picornavirus VP3/VP1 cleavage site disrupt in vitro processing and assembly of capsid precursors.

Authors:  G D Parks; A C Palmenberg
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  An apparent deletion of an oligonucleotide detected by RNA fingerprint in the nondiabetogenic B variant of encephalomyocarditis virus is caused by a point mutation.

Authors:  J W Yoon; A K Wong; Y S Bae; H M Eun
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

4.  Proteolytic activity of hepatitis A virus 3C protein.

Authors:  X Y Jia; E Ehrenfeld; D F Summers
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

Review 5.  Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes.

Authors:  W G Dougherty; B L Semler
Journal:  Microbiol Rev       Date:  1993-12

6.  Mutational analysis of the encephalomyocarditis virus primary cleavage.

Authors:  H Hahn; A C Palmenberg
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

7.  Degradation of cellular proteins during poliovirus infection: studies by two-dimensional gel electrophoresis.

Authors:  A Urzainqui; L Carrasco
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  Effects of cDNA hybridization on translation of encephalomyocarditis virus RNA.

Authors:  D S Shih; I W Park; C L Evans; J M Jaynes; A C Palmenberg
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

9.  Divergent transcription of early 35- and 94-kilodalton protein genes encoded by the HindIII K genome fragment of the baculovirus Autographa californica nuclear polyhedrosis virus.

Authors:  P D Friesen; L K Miller
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

10.  The nucleotide and deduced amino acid sequences of the encephalomyocarditis viral polyprotein coding region.

Authors:  A C Palmenberg; E M Kirby; M R Janda; N L Drake; G M Duke; K F Potratz; M S Collett
Journal:  Nucleic Acids Res       Date:  1984-03-26       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.